Ocular Therapeutix Inc. (NASDAQ:OCUL) shares rose 1% during mid-day trading on Tuesday . The company traded as high as $5.01 and last traded at $4.95, with a volume of 193,171 shares trading hands. The stock had previously closed at $4.90.

OCUL has been the subject of a number of recent research reports. Zacks Investment Research upgraded Ocular Therapeutix from a “sell” rating to a “buy” rating and set a $9.25 price objective for the company in a research note on Thursday, March 17th. Cowen and Company reiterated a “buy” rating on shares of Ocular Therapeutix in a research note on Monday, June 6th. Morgan Stanley reiterated a “buy” rating on shares of Ocular Therapeutix in a research note on Saturday, April 9th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $48.00 price objective on shares of Ocular Therapeutix in a research note on Sunday, April 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $31.85.

The firm has a 50-day moving average of $7.77 and a 200-day moving average of $8.74. The firm’s market capitalization is $126.80 million.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.01. The firm earned $458 million during the quarter. On average, equities analysts expect that Ocular Therapeutix Inc. will post ($1.86) EPS for the current fiscal year.

In other Ocular Therapeutix news, CEO Amarpreet Sawhney acquired 10,000 shares of the stock in a transaction dated Thursday, June 9th. The stock was purchased at an average price of $6.70 per share, with a total value of $67,000.00. Following the transaction, the chief executive officer now directly owns 573,733 shares of the company’s stock, valued at $3,844,011.10. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.